Market Realities & Availability (Brief Retail Snapshot)

Basic Tacrolimus Information

• INN (International Nonproprietary Name): Tacrolimus
• Brand Names Available In United Kingdom: Prograf®, Advagraf®, Protopic® (brands and generics available internationally and in the EU; UK supply commonly reflects these manufacturers and authorised generics)
• ATC Code: L04AD02 (systemic calcineurin inhibitor); D11AH01 (topical dermatological)
• Forms & Dosages: Capsules 0.5mg, 1mg, 5mg; Extended‑release caps 0.5–5mg; IV 5mg/ml vials; Ointment 0.03% and 0.1% (10g/30g/60g)
• Manufacturers In United Kingdom: Astellas Pharma (Prograf®, Protopic®, Advagraf®) and European generics suppliers such as Sandoz, Mylan and Accord Healthcare (listed as suppliers in RAW_DATA)
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription only (Rx Only) for all forms

Where Tacrolimus Is Stocked And How Patients Find It

Patients often encounter tacrolimus via two clear supply channels: hospital pharmacies for systemic use and community pharmacies for topical forms.

Hospital centres supply IV vials and prolonged‑release Advagraf® for initiation and monitored inpatient regimens.

Community pharmacies — including larger chains such as Boots and LloydsPharmacy and NHS dispensaries — commonly dispense Prograf® capsules, Protopic® ointment or generics substituted at dispensing.

Topical tacrolimus is easier for local pharmacies to stock and patients frequently search for tacrolimus ointment online or Prograf UK availability.

Electronic Prescription Service (EPS) has made collection from community pharmacy more convenient, while clinic‑led IV initiation and therapeutic drug monitoring remain hospital‑centred.

Online pharmacies and clinic dispensaries are growing as access routes, but prescriptions remain compulsory for all forms.

Practical Note For Retail Stock

Stock of systemic strengths and IV vials is commonly limited to hospital pharmacies and specialist centres.

Topical ointments (0.03% and 0.1%) and basic capsule strengths are more likely to be available in larger community chains.

Patients and teams should routinely check MHRA recalls and the SmPC before dispensing or purchase.

When a community pharmacy does not hold a brand, prescribers may specify "do not substitute" for narrow therapeutic index reasons; confirm with prescriber.

Patient Experiences & Common Use Cases

Real Patient Concerns And Daily Realities

Which patients use tacrolimus and what do they worry about?

Two common pathways appear in practice: lifelong systemic therapy following organ transplant and intermittent topical use for atopic dermatitis flares.

Transplant recipients describe the regular burden of therapeutic drug monitoring, clinic blood tests and vigilance for drug interactions.

Typical systemic side effects reported include tremor, raised blood pressure and metabolic changes such as hyperglycaemia.

Dermatology patients often report quick relief from itch with tacrolimus ointment, balanced against transient site burning or stinging on application.

Adherence challenges are common and include twice‑daily dosing for immediate‑release capsules and the need to remember clinic blood tests.

Misconceptions exist that topical tacrolimus is available over the counter, so many patients search “tacrolimus ointment for eczema” before consulting clinicians.

Practical Counselling Points

• Explain Rx‑Only Status: Make clear systemic formulations require a prescription and routine TDM.
• Topical Use Advice: Warn that transient burning is common and to avoid occlusion unless advised by a clinician.
• NHS Support: Signpost transplant nurses, dermatology clinics and community pharmacist consultations for ongoing support.

Purchasing: NHS Vs Private, Pricing & Reimbursement

How UK Patients Pay And Where Costs Differ

Who funds tacrolimus in the UK and what are the patient costs?

Systemic tacrolimus for transplant patients is usually funded by the NHS as part of lifelong immunosuppression care.

Topical tacrolimus may be prescribed on the NHS for moderate to severe atopic dermatitis when clinically appropriate.

Prescription charging is regionally variable: prescriptions are free in Scotland, Wales and Northern Ireland.

In England, patients pay a prescription charge unless they meet an exemption.

Private prescriptions and self‑pay online purchases exist; prices vary by brand and pack size and generics such as PanGraf® are typically cheaper.

Hospital pharmacies usually dispense hospital‑initiated brands such as Advagraf® and IV Prograf®, whereas community pharmacists may substitute authorised generics unless "do not substitute" is specified.

Buying Tips

• Ask the pharmacist about generic options and check the MHRA‑approved SmPC for the prescribed brand.
• When ordering online verify GPhC registration and inspect packaging and patient leaflets for national language and authenticity.

Product Forms & Strengths (What's On The Shelf)

Quick Reference To Formulations For Dispensing

Which formulations should pharmacy teams expect to see in practice?

Available systemic forms include immediate‑release capsules 0.5mg, 1mg and 5mg and extended‑release (Advagraf®) capsules 0.5–5mg.

IV tacrolimus is supplied as 5mg/ml ampoules or vials for perioperative and acute use and is typically managed by hospital pharmacy.

Topical preparations most commonly seen are Protopic® ointment 0.03% and 0.1% in 10g, 30g and 60g aluminium tubes.

Packaging conventions: foil blisters for capsules, glass ampoules or vials for IV and aluminium tubes for ointment.

Community pharmacies commonly hold topical ointments and some capsule strengths; hospitals maintain a wider range including IV and prolonged‑release products.

Dispensing Checklist

• Check expiry date and batch number; record batch for traceability.
• Confirm leaflet and carton language for imported packs.
• Follow storage instructions: IV refrigerated (2–8°C); caps/ointments stored below 25°C.

Indications And Typical Regimens (Practical Dosing)

Standard Doses By Indication For Pharmacy Reference

What are the common regimens you will see on prescriptions?

For renal or hepatic transplant adults, oral tacrolimus is typically started at 0.1–0.2 mg/kg/day divided every 12 hours.

Cardiac transplant dosing commonly begins around 0.075 mg/kg/day divided every 12 hours.

Children often require higher mg/kg doses (around 0.15–0.2 mg/kg/day divided) and absorption is more variable.

Advagraf® prolonged‑release capsules provide once‑daily dosing and are available in 0.5mg to 5mg strengths for maintenance therapy.

Topical tacrolimus ointment (0.03% or 0.1%) is typically applied as a thin layer twice daily to affected areas for 2–6 weeks during flares.

Emphasise that tacrolimus has a narrow therapeutic index and dosing must be individualised and tied to trough blood level targets and clinical response.

Practical Pharmacy Notes

• Never advise dose changes; refer dosage queries to the MDT or prescriber.
• When switching immediate‑release to prolonged‑release, confirm equivalent daily total dose with the prescriber and ensure TDM is planned.

How To Use: Administration, Storage, Missed Doses

Clear Counselling Script For Patients

How should patients take and keep tacrolimus?

Oral capsules are usually taken consistently with regard to food, because absorption is affected by meals; advise patients to follow the regimen given by their team.

Advagraf® extended‑release capsules are given once daily, commonly in the morning, as instructed by the prescriber.

For topical therapy, apply a thin layer of ointment to the affected skin twice daily and avoid contact with eyes and mucous membranes.

Capsules and ointments should be stored below 25°C in original packaging and protected from moisture and light.

IV vials must be refrigerated at 2–8°C and must not be frozen; use immediate dilution and administration per hospital protocol.

If a dose is missed, take it as soon as remembered if within 4–6 hours; otherwise skip that dose and continue the usual schedule without doubling up.

In case of overdose seek immediate medical attention because of risks such as nephrotoxicity and neurotoxicity.

Visual Aids For Dispensing

• Capsule: Store below 25°C; keep in blister until dispensing.
• IV Vial: Refrigerate 2–8°C; label refrigerated supply clearly.
• Ointment: Store below 25°C; avoid freezing and keep tube cap tight.

Safety Profile & Common Adverse Reactions

What To Warn Patients About, And When To Escalate

Which side effects should patients expect and which require urgent assessment?

Common systemic adverse reactions include headache, hypertension, nausea, tremor and metabolic abnormalities such as hyperglycaemia and hyperkalaemia.

The major systemic safety concerns are nephrotoxicity and neurotoxicity, which require prompt clinical review if suspected.

Topical reactions are usually local and include burning, pruritus and erythema; systemic absorption from ointment is rare (<0.5%).

Pharmacy teams should counsel patients to monitor for signs of infection and to seek urgent GP or hospital care for severe symptoms such as reduced urine output, marked tremor or visual disturbances.

Record and report adverse drug reactions in the patient record and via Yellow Card reporting when appropriate.

Monitoring Prompts For Pharmacy Teams

• Check for concomitant nephrotoxic medicines such as aminoglycosides or NSAIDs.
• Recommend baseline and ongoing blood pressure and glucose monitoring for new systemic starts.

Drug Interactions & Therapeutic Drug Monitoring (TDM)

High‑Risk Interactions And What To Do At The Counter

Which drugs commonly interact with tacrolimus and what action should a pharmacist take?

Tacrolimus is metabolised by CYP3A4/5 and has highly variable pharmacokinetics with many interaction risks.

CYP3A4 inhibitors such as macrolide antibiotics and azole antifungals often raise tacrolimus blood levels and increase nephrotoxicity risk.

CYP3A4 inducers such as certain anticonvulsants can lower levels and raise the risk of graft rejection.

Other interacting groups include calcium‑channel blockers, some statins and grapefruit juice, all of which can alter tacrolimus exposure.

Systemic tacrolimus always requires routine therapeutic drug monitoring with trough blood levels and dose adjustments guided by the clinical team.

Practical Steps When An Interaction Arises

• Contact the prescriber to agree a monitoring plan and possible dose adjustment.
• Document communications and advise the patient to report new antibiotics or antifungals started elsewhere.

Contraindications & Special Precautions

Who Should Not Take Tacrolimus And When To Pause

Which patients should not receive tacrolimus and what precautions matter at the pharmacy?

Absolute contraindications include hypersensitivity to tacrolimus or excipients.

Relative contraindications and important warnings include pre‑existing renal or hepatic dysfunction and uncontrolled infection.

Caution is needed with concurrent nephrotoxic or ototoxic drugs and in patients with significant cardiac disease.

Pregnancy and breastfeeding require specialist discussion; systemic use is only when benefits outweigh risks.

For topical use, avoid applying to sites of active skin infection and advise patients to report signs of local infection.

Decision Aids For Pharmacists

• Quick checklist: allergy history, recent renal/liver function, infection status, current medicines list.
• Always check the SmPC and MHRA alerts when in doubt.

Special Populations: Children, Elderly, Pregnancy, Renal/Hepatic Impairment

Dose Adjustments And Monitoring Considerations

How do dose and monitoring differ in vulnerable groups?

Children usually need higher mg/kg dosing and closer monitoring because of variable absorption and metabolic differences.

Elderly patients often require cautious initiation and possible dose reductions due to comorbidities and higher nephrotoxicity risk.

Renal or hepatic impairment necessitates dose reduction and closer therapeutic drug monitoring to avoid toxicity.

Pregnancy and breastfeeding should prompt referral to specialist services; systemic tacrolimus is used only if the perceived benefit outweighs potential risks.

For topical therapy prefer 0.03% in under‑16s for better safety data, reserving 0.1% for adults where clinically needed.

Clinic Handover Points

• Flag paediatric and geriatric patients for hospital pharmacist review on any change of brand or formulation.
• Ensure community follow‑up is arranged for biochemical monitoring after discharge or initiation.

Switching Brands, Generics And Bioequivalence

Practical Pharmacy Switching Rules

What must pharmacists check before substituting one tacrolimus brand or formulation for another?

Small pharmacokinetic differences between brands can affect trough levels for this narrow therapeutic index drug.

Immediate‑release Prograf® (q12h) and prolonged‑release Advagraf® (once daily) are not interchangeable on a simple mg‑for‑mg basis without clinical review.

Where prescribers write "do not substitute", that instruction must be followed for systemic tacrolimus unless the prescriber agrees otherwise.

If a substitution occurs arrange for extra therapeutic drug monitoring and notify the transplant or prescribing team to agree any dose changes.

Patient Communication Points

• Explain clearly why a switch is recommended and what extra blood tests may be needed.
• Check patient understanding and provide a clear safety‑net to report new symptoms after a switch.

Pharmacy Stock, Supply Chain & Storage Logistics

Handling Requirements And Shortage Mitigation

What storage rules and contingency steps should teams follow?

Store capsules and ointments below 25°C in original packaging and protect from moisture and light.

IV vials require refrigerated storage at 2–8°C and must not be frozen, with strict cold‑chain management for hospital pharmacy.

Supply interruptions can occur and manufacturers include Astellas, Sandoz, Mylan and a range of Indian generics; register for MHRA and manufacturer shortage alerts.

Document batch numbers and maintain traceability for each dispensing event, especially during shortages or imports with differing carton language.

For online orders ensure GPhC compliance and authenticity checks given the variation in international packaging and leaflets.

Dispensing Best Practice

• Verify leaflet language and patient information for imported brands.
• Label refrigerated items clearly and advise patients to return IV vials to the fridge promptly when required for outpatient administration.

Practical Counselling & Pharmacist Checklist

Key Messages To Deliver At Point Of Dispense

What must every patient leaving the pharmacy understand about tacrolimus?

Explain the purpose of the medicine: systemic immunosuppression or topical anti‑inflammatory use for skin disease.

Reinforce the importance of dosing schedule and therapeutic drug monitoring for systemic formulations.

Warn about potential serious side effects including nephrotoxicity, tremor and infection and advise when to seek urgent care.

Cover interactions, especially CYP3A4 inhibitors/inducers and grapefruit avoidance, and storage instructions including refrigeration where required.

For topical users demonstrate application technique, warn about transient burning and emphasise not to apply near eyes or mouth.

Provide written patient information and signpost to transplant nurses or dermatology clinics for follow‑up.

Pharmacist Counselling Checklist

• Confirm indication, dose, frequency and formulation.
• Confirm understanding of monitoring requirements and when to seek help.
• Provide a patient handout summarising side effects, storage and missed dose advice.

Competitors, Off‑Label Uses & Concise Clinical Context

Alternatives, Off‑Label Searches And Evidence Pointers

Which alternative agents and off‑label uses are commonly considered?

Competing systemic agents include ciclosporin (Sandimmun®) and sirolimus (Rapamune®), both used in transplant medicine with differing monitoring needs.

Topical alternatives for atopic dermatitis include pimecrolimus (Elidel®) where appropriate.

Off‑label topical uses such as lichen planus and vitiligo have been reported but evidence varies and prescribers should consult SmPCs and local formularies.

Tacrolimus is a calcineurin inhibitor with ATC code L04AD02 systemically and D11AH01 topically and has robust evidence for prevention of graft rejection and for topical control of atopic dermatitis flares.

Pharmacy pages should routinely link to SmPC and MHRA guidance and signpost local transplant centre guidance and patient support groups where available.

Where To Find More Authoritative Info

• MHRA product safety updates and the European SmPC documents.
• NHS medicines pages and transplant centre protocols for local practice.

Delivery Across United Kingdom

Note: In our online pharmacy, tacrolimus is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.